Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.61 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.61 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591303 | 0.88 | KDM4E (0.66) | SMN1; SMN2ALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL4525519 | 0.85 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL17790726 | 0.84 | CNR1 (0.68) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL14991782 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL14241870 | 0.84 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL884912 | 0.83 | NPC1 (0.55) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL29937482 | 0.83 | NPC1 (0.55) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL14559555 | 0.83 | CNR1 (0.66) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL12862951 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL31579654 | 0.82 | CNR1 (0.57) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024213089-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海壹迪生物技术有限公司 | 2024-10-17 | — | — | WO | disclosed |
| EP-3736268-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3235815-A1 | AGENTS AGAINST PARASITIC HELMINTHS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9783505-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9556126-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160354374-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-12-08 | — | — | US | disclosed |
| EP-3082819-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010120943-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-1131312-B1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP LTD (KR) | 2005-10-26 | — | — | EP | disclosed |
| US-6545008-B1 | Inhibitory activity against gastric acid secretion | YUHAN CORPORATION (KR) | 2003-04-08 | — | — | US | disclosed |
| EP-1131312-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029403-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354374-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | PRKCQ, PRKCH, PRKCE | SMN1; SMN2 1467/4885ALDH1A1 3945/4885KMT2A 1138/4885 |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | SMN1; SMN2 2591/4885ALDH1A1 4349/4885KMT2A 4765/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | SMN1; SMN2 2796/4885ALDH1A1 3983/4885KMT2A 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.